Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.
about
PEGylated Adenoviruses: From Mice to MonkeysNeuroanatomy goes viral!Progress and prospects: immune responses to viral vectorsAdenoviral vector immunity: its implications and circumvention strategies.Hepatic gene transfer as a means of tolerance induction to transgene productsα-Galactosidase A expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine traffickingSpecies differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusOptimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategiesInfluence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.Genetically reprogrammed, liver-derived insulin-producing cells are glucose-responsive, but susceptible to autoimmune destruction in settings of murine model of type 1 diabetes.Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infectionGene therapy for inborn errors of liver metabolism: progress towards clinical applicationsAn adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice.Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance.Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors.New insights on adenovirus as vaccine vectors.Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis.Viral hybrid vectors for somatic integration - are they the better solution?Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions.The evolution of adenoviral vectors through genetic and chemical surface modifications.Lung gene therapy-How to capture illumination from the light already present in the tunnel.Adenoviral gene therapy in hepatocellular carcinoma: a review.Standard free droplet digital polymerase chain reaction as a new tool for the quality control of high-capacity adenoviral vectors in small-scale preparations.An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.In vivo reduction or blockade of interleukin-1β in primary osteoarthritis influences expression of mediators implicated in pathogenesis.Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.Gene therapy with nonviral poly(ε-caprolactone) nanoparticles.Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors.
P2860
Q24635276-B5B82F62-6407-436D-B315-EC7F9DC0DD8AQ26802140-1660152C-9D2B-4370-9A2C-340022D20182Q28264531-68BAC1CC-9B3A-4D79-A73F-481A0A090811Q33565630-82C7E2F3-44C7-4375-BE68-1C56777086C4Q33775537-9E7401A9-12D7-4B2C-B860-88295568EFFDQ34671627-6F9269F8-4448-4DEC-8041-24DA1236485EQ34975214-D8C9463A-FEA5-47E5-AD14-492C41078DCCQ35666180-BCE562CB-6CF8-4466-8F40-F0C6F61D07ABQ35884548-E5B97684-E7E2-4BB2-ADAC-8FDE7A2740DFQ36395442-5C61DAAF-D42B-45BF-A826-A680B3C92461Q36729250-AFD3A1B4-347F-446E-AB51-A09D206F578FQ36932523-A43DFBEA-FC66-4E8A-892B-2D54A7867E25Q37015311-CD51AE4B-62BA-4FC7-A75E-4E6B47238505Q37118764-94EC9E45-65D3-420F-8E69-A69626DDB4BAQ37241434-7AA4F209-F7E3-46F1-BD6F-3C6427704BFFQ37256197-6668192C-6671-4DB8-9324-103FB09907DAQ37398067-F5A93E8A-5ADA-4D1F-80E3-4C6A62731340Q37513550-F4C7A0B3-287A-4C8E-968A-9C80D36FAC86Q37690581-E1529115-A3D1-4382-B9C8-134D3B01EA24Q37807993-0CE5AC66-5C65-415C-B99D-43C328923D0EQ37945189-34B5915B-065D-4E84-885C-358EE220E3D5Q37977063-78C8D287-B685-45A3-A9E2-E69B895AAD87Q38189250-E82E06D8-9924-484F-AC2E-0198CFE3BD6DQ38544793-59B497BA-2FB7-4D3A-8910-83CCA551321EQ38552204-B765504B-FFF7-4FD8-A73D-8ED4BD0D3591Q38914385-A24D96EC-7CCB-4717-A893-3883DDDD2A87Q39308911-00D438D4-ABF3-4B9B-9139-44FA6868E872Q42079303-C40E9545-D931-4357-BA4D-98BEA6198B18Q45863903-CC8554B6-355D-4196-A99F-8590F74A6E6DQ45878200-495FB061-11DB-4FEC-A511-00C014B3B2CAQ51857382-D129D6AD-CDC6-4584-BDAC-F5AC58320978
P2860
Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immune response to helper depe ...... apy: challenges and prospects.
@en
type
label
Immune response to helper depe ...... apy: challenges and prospects.
@en
prefLabel
Immune response to helper depe ...... apy: challenges and prospects.
@en
P1433
P1476
Immune response to helper depe ...... rapy: challenges and prospects
@en
P2093
Brendan Lee
Michael P Seiler
P304
P356
10.2174/156652307782151452
P407
P577
2007-10-01T00:00:00Z